Idexx Laboratories (IDXX) Receivables - Net (2009 - 2026)

Idexx Laboratories has reported Receivables - Net for 18 years, with the latest figure at $627.1 million in Q2 2026.

• On a quarterly basis, Receivables - Net rose 11.87% year-over-year to $627.1 million in Q2 2026; TTM through Jun 2026 was $627.1 million, a 11.87% increase from a year earlier, with the FY2025 full-year figure at $552.4 million, up 16.64% from the prior year.
• Receivables - Net was $627.1 million for Q2 2026 at Idexx Laboratories, up from $603.5 million in the prior quarter.
• The five-year high for Receivables - Net was $627.1 million in Q2 2026, with the low at $388.1 million in Q3 2022.
• Average Receivables - Net over 5 years is $493.6 million, with a median of $490.4 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net advanced 3.0% in 2022, then gained 16.65% in 2023.
• Over 5 years, Receivables - Net stood at $400.6 million in 2022, then gained by 14.18% to $457.4 million in 2023, then increased by 3.53% to $473.6 million in 2024, then climbed by 16.64% to $552.4 million in 2025, then advanced by 13.52% to $627.1 million in 2026.
• The last three Receivables - Net figures came in at $627.1 million (Q2 2026), $603.5 million (Q1 2026), and $552.4 million (Q4 2025), per Business Quant data.